NEW YORK (Reuters) -Novo Nordisk CEO Mike Doustdar said during a White House event on Thursday that the company’s bid for obesity biotech Metsera is higher than the one from rival Pfizer Inc., which has sued both Metsera and Novo over the terms of their rival deal.
“As of today, our bid is higher, and our message to Pfizer is that if they would like to buy the company, then put your hand in the pocket and bid higher,” Doustdar said.
(Reporting by Bhargav Acharya)
Brought to you by www.srnnews.com
